Labcorp Holdings Inc. (LH) Investor Relations Documents

Labcorp Holdings Inc. (LH) investor relations documents from the company's IR site: 10 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-17	Press release	Labcorp to Host Investor Day on September 10, 2026
2026-08-10	Press release	Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
2026-08-04	Press release	Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
2026-07-30	Press release	Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
2026-07-27	Press release	Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
2026-07-09	Press release	Labcorp Declares Quarterly Dividend
2026-06-30	Press release	Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
2026-06-22	Press release	Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Scre
2026-05-29	Press release	Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
2026-05-28	Press release	Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

LH overview · LH earnings · LH financials · LH KPIs · LH documents · LH ownership · LH peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.